Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas and Aveo end tivozanib collaboration

Astellas and Aveo end tivozanib collaboration

17th February 2014

Astellas and Aveo Oncology have decided to end the collaborative development of a new cancer drug for strategic reasons.

The worldwide collaboration and license agreement for the development and commercialisation of tivozanib has been terminated by Astellas based on the clinical status of the three indications studied.

Following this decision, the partnership will end on August 11th 2014, with an ongoing study of the drug as a treatment for colorectal cancer to be cancelled. Tivozanib rights will be returned to Aveo after this point.

Yoshihiko Hatanaka, president and chief executive officer of Astellas, said: "While our decision is based on strategic reasons, Astellas is proud of our partnership and work with Aveo. We remain committed to the field of Oncology to help meet the unmet needs of cancer patients."

This comes after Astellas founded a new business division, Astellas Innovation Management, last year for the specific purpose of overseeing external strategic alliance activities. Since then, it has been able to agree new partnership deals with ClearPath Development Company and Accenture.ADNFCR-8000103-ID-801694117-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.